Mitsubishi Tanabe, Janssen Revise Copromotion Framework for Stelara

June 29, 2018
Mitsubishi Tanabe Pharma said on June 28 that it has updated the framework of its existing copromotion deal with Janssen Pharmaceutical for the anti-IL-12/23 p40 monoclonal antibody Stelara (ustekinumab). The two companies have been copromoting the therapy for Crohn’s disease...read more